{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:50:11Z","timestamp":1792799411459,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["097395\/Z\/11\/Z"],"award-info":[{"award-number":["097395\/Z\/11\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malaria continues to be a pressing global health issue, causing nearly half a million deaths per year. An effective malaria vaccine could radically improve our ability to control and eliminate this pathogen. The most advanced malaria vaccine, RTS,S, confers only 30% protective efficacy under field conditions, and hence the search continues for improved vaccines. New antigens and formulations are always first developed at a pre-clinical level. This paper describes the development of a platform to supplement existing tools of pre-clinical malaria vaccine development, by displaying linear peptides on a virus-like particle (VLP). Peptides from PfCSP, particularly from outside the normal target of neutralizing antibodies, the central NANP repeat region, are screened for evidence of protective efficacy. One peptide, recently identified as a target of potent neutralizing antibodies and lying at the junction between the N-terminal domain and the central repeat region of PfCSP, is found to confer protective efficacy against malaria sporozoite challenge in mice when presented on the Q\u03b2 VLP. The platform is also used to explore the effects of increasing numbers of NANP unit repeats, and including a universal CD4<jats:sup>+<\/jats:sup>T-cell epitope from tetanus toxin, on immunogenicity and protective efficacy. The VLP-peptide platform is shown to be of use in screening malaria peptides for protective efficacy and answering basic vaccinology questions in a pre-clinical setting.<\/jats:p>","DOI":"10.1038\/s41541-021-00302-x","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:03:08Z","timestamp":1617271388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development"],"prefix":"10.1038","volume":"6","author":[{"given":"Erwan","family":"Atcheson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-1696","authenticated-orcid":false,"given":"Arturo","family":"Reyes-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"302_CR1","unstructured":"World Health Organization (WHO). World Malaria Report 2016 (2016)."},{"key":"302_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"RTS,S Clinical Trials Partnership.","year":"2014","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11, e1001685 (2014).","journal-title":"PLoS Med."},{"key":"302_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","volume":"387","author":"MA Penny","year":"2016","unstructured":"Penny, M. A. et al. Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet 387, 367\u2013375 (2016).","journal-title":"Lancet"},{"key":"302_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/328257a0","volume":"328","author":"DA Herrington","year":"1987","unstructured":"Herrington, D. A. et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257\u2013259 (1987).","journal-title":"Nature"},{"key":"302_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.2988126","volume":"228","author":"WR Ballou","year":"1985","unstructured":"Ballou, W. R. et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 228, 996\u2013999 (1985).","journal-title":"Science"},{"key":"302_CR6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1126\/science.2988125","volume":"228","author":"JF Young","year":"1985","unstructured":"Young, J. F. et al. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine. Science 228, 958\u2013962 (1985).","journal-title":"Science"},{"key":"302_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4269\/ajtmh.1991.45.533","volume":"45","author":"SG Vreden","year":"1991","unstructured":"Vreden, S. G., Verhave, J. P., Oettinger, T., Sauerwein, R. W. & Meuwissen, J. H. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am. J. Trop. Med. Hyg. 45, 533\u2013538 (1991).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"302_CR8","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","volume":"171","author":"DM Gordon","year":"1995","unstructured":"Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576\u20131585 (1995).","journal-title":"J. Infect. Dis."},{"key":"302_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep19234","volume":"6","author":"KD Brune","year":"2016","unstructured":"Brune, K. D. et al. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci. Rep. 6, 19234 (2016).","journal-title":"Sci. Rep."},{"key":"302_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1086\/427243","volume":"191","author":"P Bejon","year":"2005","unstructured":"Bejon, P. et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191, 619\u2013626 (2005).","journal-title":"J. Infect. Dis."},{"key":"302_CR11","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4049\/jimmunol.1100302","volume":"187","author":"A Reyes-Sandoval","year":"2011","unstructured":"Reyes-Sandoval, A. et al. CD8+ T effector memory cells protect against liver-stage malaria. J. Immunol. 187, 1347\u20131357 (2011).","journal-title":"J. Immunol."},{"key":"302_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209028","volume":"14","author":"E Atcheson","year":"2019","unstructured":"Atcheson, E., Bauza, K. & Reyes-Sandoval, A. A probabilistic model of pre-erythrocytic malaria vaccine combination in mice. PLoS ONE 14, e0209028 (2019).","journal-title":"PLoS ONE"},{"key":"302_CR13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/eji.200526285","volume":"35","author":"P Maurer","year":"2005","unstructured":"Maurer, P. et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol. 35, 2031\u20132040 (2005).","journal-title":"Eur. J. Immunol."},{"key":"302_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"302_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med."},{"key":"302_CR16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","volume":"212","author":"DA Espinosa","year":"2015","unstructured":"Espinosa, D. A. et al. Proteolytic cleavage of the plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J. Infect. Dis. 212, 1111\u20131119 (2015).","journal-title":"J. Infect. Dis."},{"key":"302_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep46621","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C. & Hill, A. V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci. Rep. 7, 46621 (2017).","journal-title":"Sci. Rep."},{"key":"302_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.vaccine.2008.09.097","volume":"27","author":"SE Bongfen","year":"2009","unstructured":"Bongfen, S. E. et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27, 328\u2013335 (2009).","journal-title":"Vaccine"},{"key":"302_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124856","volume":"10","author":"DC Whitacre","year":"2015","unstructured":"Whitacre, D. C. et al. P. falciparum and P. vivax epitope-focused VLPs elicit sterile immunity to blood stage infections. PLoS ONE 10, e0124856 (2015).","journal-title":"PLoS ONE"},{"key":"302_CR20","doi-asserted-by":"publisher","first-page":"20524","DOI":"10.1074\/jbc.M414254200","volume":"280","author":"D Rathore","year":"2005","unstructured":"Rathore, D. et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J. Biol. Chem. 280, 20524\u201320529 (2005).","journal-title":"J. Biol. Chem."},{"key":"302_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.20101488","volume":"208","author":"A Coppi","year":"2011","unstructured":"Coppi, A. et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341\u2013356 (2011).","journal-title":"J. Exp. Med."},{"key":"302_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1128\/CVI.00066-13","volume":"20","author":"MD Porter","year":"2013","unstructured":"Porter, M. D. et al. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin. Vaccin. Immunol. 20, 803\u2013810 (2013).","journal-title":"Clin. Vaccin. Immunol."},{"key":"302_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.171.1.299","volume":"171","author":"JP Tam","year":"1990","unstructured":"Tam, J. P. et al. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 171, 299\u2013306 (1990).","journal-title":"J. Exp. Med."},{"key":"302_CR24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4049\/jimmunol.149.2.717","volume":"149","author":"D Valmori","year":"1992","unstructured":"Valmori, D., Pessi, A., Bianchi, E. & Corradin, G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149, 717\u2013721 (1992).","journal-title":"J. Immunol."},{"key":"302_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1590\/S0074-02761994000600017","volume":"89","author":"MA Herrera","year":"1994","unstructured":"Herrera, M. A., de Plata, C., Gonz\u00e1lez, J. M., Corradin, G. & Herrera, S. Immunogenicity of multiple antigen peptides containing Plasmodium vivax CS epitopes in BALB\/c mice. Mem. Inst. Oswaldo Cruz 89, 71\u201376 (1994).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"302_CR26","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.4049\/jimmunol.154.6.2784","volume":"154","author":"R Wang","year":"1995","unstructured":"Wang, R. et al. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 154, 2784\u20132793 (1995).","journal-title":"J. Immunol."},{"key":"302_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4269\/ajtmh.1997.56.200","volume":"56","author":"WE Collins","year":"1997","unstructured":"Collins, W. E. et al. Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax. Am. Am. J. Trop. Med. Hyg. 56, 200\u2013210 (1997).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"302_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0264-410X(97)00200-4","volume":"15","author":"C Yang","year":"1997","unstructured":"Yang, C. et al. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin. Vaccine 15, 377\u2013386 (1997).","journal-title":"Vaccine"},{"key":"302_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0264-410X(99)00184-X","volume":"18","author":"CA Moreno","year":"1999","unstructured":"Moreno, C. A. et al. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice. Vaccine 18, 89\u201399 (1999).","journal-title":"Vaccine"},{"key":"302_CR30","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1086\/315871","volume":"182","author":"EH Nardin","year":"2000","unstructured":"Nardin, E. H. et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182, 1486\u20131496 (2000).","journal-title":"J. Infect. Dis."},{"key":"302_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4049\/jimmunol.166.1.481","volume":"166","author":"EH Nardin","year":"2001","unstructured":"Nardin, E. H. et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 166, 481\u2013489 (2001).","journal-title":"J. Immunol."},{"key":"302_CR32","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1128\/IAI.00533-10","volume":"78","author":"B Mahajan","year":"2010","unstructured":"Mahajan, B. et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect. Immun. 78, 4613\u20134624 (2010).","journal-title":"Infect. Immun."},{"key":"302_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fimmu.2017.00226","volume":"8","author":"AC Gomes","year":"2017","unstructured":"Gomes, A. C. et al. Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines. Front. Immunol. 8, 226 (2017).","journal-title":"Front. Immunol."},{"key":"302_CR34","doi-asserted-by":"publisher","first-page":"e00114","DOI":"10.1128\/IAI.00114-18","volume":"86","author":"E Atcheson","year":"2018","unstructured":"Atcheson, E. et al. Tailoring a Plasmodium vivax vaccine to enhance efficacy through a combination of a CSP virus-like particle and TRAP viral vectors. Infect. Immun. 86, e00114\u201318 (2018). (9).","journal-title":"Infect. Immun."},{"key":"302_CR35","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1086\/513996","volume":"175","author":"L Grangeot-Keros","year":"1997","unstructured":"Grangeot-Keros, L. et al. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J. Infect. Dis. 175, 944\u2013946 (1997).","journal-title":"J. Infect. Dis."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00302-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00302-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00302-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:58:12Z","timestamp":1698843492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00302-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00302-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"17 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}